NCT03515096View on ClinicalTrials.gov

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

August 2, 2021

Study Completion Date

July 1, 2022

Conditions
EltrombopagHematopoietic Stem Cell TransplantationThrombocytopenia
Interventions
DRUG

Eltrombopag

Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.

DRUG

rhTPO

rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.

Trial Locations (1)

518035

Shenzhen Second People's Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen Second People's Hospital

OTHER

NCT03515096 - Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT | Biotech Hunter | Biotech Hunter